Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 2/20 | 0.75 |
| ▸ | MMP9 | P14780 | 2/20 | 0.75 |
| ▸ | MMP8 | P22894 | 2/20 | 0.75 |
| ▸ | MMP13 | P45452 | 2/20 | 0.75 |
| ▸ | CHEK2 | O96017 | 10/20 | 0.72 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.70 |
| ▸ | NPC1 | O15118 | 1/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
| ▸ | PKM | P14618 | 1/20 | 0.70 |
| ▸ | HPGD | P15428 | 1/20 | 0.70 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.70 |
| ▸ | RAB9A | P51151 | 1/20 | 0.70 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.70 |
| ▸ | RELA | Q04206 | 1/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.70 |
| ▸ | RHEB | Q15382 | 1/20 | 0.69 |
| ▸ | ATM | Q13315 | 1/20 | 0.61 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20982471 | 0.92 | MMP2 (0.78) | MMP2MMP9MMP8MMP13CHEK2 | |
| SCHEMBL14381943 | 0.90 | KDM4E (0.70) | MMP2MMP9MMP8MMP13CHEK2 | |
| SCHEMBL20982644 | 0.89 | NR4A2 (0.86) | MMP2MMP9MMP8MMP13CHEK2 | |
| SCHEMBL2617479 | 0.88 | KDM4E (0.71) | MMP2MMP9MMP8MMP13CHEK2 | |
| SCHEMBL5219768 | 0.87 | NR4A2 (0.83) | MMP2MMP9MMP8MMP13CHEK2 | |
| SCHEMBL19763371 | 0.87 | CHEK2 (0.72) | MMP2MMP9MMP8MMP13CHEK2 | |
| SCHEMBL1662761 | 0.87 | CHEK2 (0.93) | MMP2MMP9MMP8MMP13CHEK2 | |
| SCHEMBL30406138 | 0.86 | MMP2 (0.73) | MMP2MMP9MMP8MMP13CHEK2 | |
| SCHEMBL19747752 | 0.86 | MMP2 (0.70) | MMP2MMP9MMP8MMP13CHEK2 | |
| SCHEMBL2563888 | 0.86 | MMP2 (0.73) | MMP2MMP9MMP8MMP13CHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7282518-B2 | Benzimidazole compounds for modulating IgE and inhibiting cellular proliferation | AVANIR PHARMACEUTICALS (US) | 2007-10-16 | — | — | US | disclosed |
| US-20070202133-A1 | BENZIMIDAZOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION | SIRCAR JAGADISH C | 2007-08-30 | — | — | US | disclosed |
| EP-1368028-B1 | BENZIMIDAZOLE COMPOUNDS FOR MODULATING IGE AND INHIBITING CELLULAR PROLIFERATION | AVANIR PHARMACEUTICALS (US) | 2007-08-15 | — | — | EP | disclosed |
| US-20040214821-A1 | Useful in the treatment of allergy and/or asthma or any diseases where Immunoglobulin E (IgE) is pathogenic; anticancer agents | SIRCAR JAGADISH C (US) | 2004-10-28 | — | — | US | disclosed |
| US-6759425-B2 | USEFUL IN THE TREATMENT OF ALLERGY AND/OR ASTHMA OR ANY DISEASES WHERE IGE IS PATHOGENIC; ALSO ARE USEFUL AS ANTICANCER AGENTS. | AVANIR PHARMACEUTICALS | 2004-07-06 | — | — | US | disclosed |
| CN-1496257-A | Benzimidazole compounds for modulating immunoglobulin E and inhibiting cell proliferation | ������˹ҩƷ��˾ | 2004-05-12 | — | — | CN | disclosed |
| EP-1368028-A1 | BENZIMIDAZOLE COMPOUNDS FOR MODULATING IGE AND INHIBITING CELLULAR PROLIFERATION | AVANIR PHARMACEUTICALS (US) | 2003-12-10 | — | — | EP | disclosed |
| WO-2002072090-A1 | BENZIMIDAZOLE COMPOUNDS FOR MODULATING IGE AND INHIBITING CELLULAR PROLIFERATION | AVANIR PHARMACEUTICALS (US) | 2002-09-19 | — | — | WO | disclosed |
| US-20020132808-A1 | Benzimidazole compounds for modulating IgE and inhibiting cellular proliferation | AVANIR PHARMACEUTICALS | 2002-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070202133-A1 | BENZIMIDAZOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION | MKI67, CMA1, CCNI | MMP2 760/4885MMP9 1867/4885MMP8 423/4885 |
| US-20040214821-A1 | Useful in the treatment of allergy and/or asthma or any diseases where Immunoglobulin E (IgE) is pathogenic; anticancer agents | FCER2, CMA1, FCGR1A | MMP2 532/4885MMP9 1719/4885MMP8 363/4885 |
| US-20020132808-A1 | Benzimidazole compounds for modulating IgE and inhibiting cellular proliferation | MKI67, CMA1, CCNI | MMP2 760/4885MMP9 1867/4885MMP8 423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.